Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BenevolentAI Limited
The new head of South Korea’s AI Drug Development Support Center talks about the country’s activities and market trends in the field, why the otherwise tech-savvy country is still lagging and what is needed to boost collaboration and the availability of big data.
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
Financing Snapshot: The AI/ML-focused company raised $101m in a series A round and plans to use the funding to develop immunoglobulin- and cell-mediated autoimmune disorder drugs.
- Artificial Intelligence
- Drug Discovery Tools
- Other Names / Subsidiaries
- BenevolentBio, BenevolentTech